In the US, longevity has been an ongoing topic over the last five years. Financing volumes increased threefold from EUR 389m to EUR 1,057m. The data suggests that the interest in European longevity research has more recently arrived. While the annual financing volume in 2017 only amounted to EUR 25m (with 16 deals), financing volumes skyrocketed to EUR 262m (with 29 deals) in 2021.
Top investors participating in the US market show significantly higher deal activities and volumes compared to investors active in Europe. Interestingly, Kizoo Technology Ventures, a Germany based fund, was among the most active investors in the US.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: